Lancet Sub-Journal: Phase I clinical phase I of the COVID-19 DNA candidate vaccine INO-4800, triggering immunogenicity in all patients

Peer-reviewed Phase I data show that inO-4800 triggers immunogenicity in 100% of subjects and induces neutral antibody and/or T-cell reactions.
the INO-4800 has good safety and tolerance and no serious adverse events are reported.
same time, the INO-4800 has thermal stability, including five years of expected shelf life at normal cooling temperatures, and eliminates the need for refrigeration transport or storage.
biotech company INOVIO is committed to introducing precision-designed DNA drugs to the market to treat and protect people from infectious diseases and cancer, and today announced that The Lancet published its Phase I clinical data.
clinical data found that the INO-4800 had good safety and tolerance and did not report serious adverse events.
only 6 level 1 adverse events (AEs) were observed, mainly injection site reactions.
it is worth noting that these AEs only occur on the day of the first or second dosing.
INO-4800 is not only safe and reliable, but can be stabilized at room temperature for more than one year, at 37 degrees Celsius for more than a month, at normal refrigeration temperature for a shelf life of five years, and no need to freeze during transport or storage.
。